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Due Care by Physicians in Use of New Drugs
Edward T. Haggins*
H OW CAREFUL must a physician be in using new drugs on his
patients? There are enough cases to give us some idea of
the proper standard of care.
A young switchboard operator sustained a cut on the middle
finger of her left hand while cleaning her glasses. She was sent
to a nearby hospital for emergency treatment by her supervisor.
Upon arriving at the hospital emergency ward, she was given a
penicillin shot followed by a skin sensitivity test in the upper
right arm to determine her susceptibility to "horse serum,"
which is the most common base used in tetanus antitoxin. Ap-
proximately five minutes later she received 1,500 units of anti-
toxin by hypodermic injection in her upper right arm. By the
time she reached her car, the sensitivity test was showing a posi-
tive reaction. Fifteen days later, a roaring began in her ears.
Five months later she suffered 50 to 55 percent permanent loss
of hearing in both ears.'
In Hackensack, New Jersey, a dentist administered the drug
"epinephrine" to a female patient before making an extraction.
This drug is used to constrict blood vessels. The patient, who
was suffering from hypertension, died of a stroke after leaving
the dentist's office.2
In a recent California case, a patient was injected intra-
venously with a dose of "Bicillin" (a pharmaceutical trade name
for a preparation of penicillin). About three hours later he ex-
perienced some itching and discomfort. Several days later his
condition worsened, with swelling about the face. He was hos-
pitalized in a serious condition. After going through a critical
stage, he recovered; however, in doing so, he suffered the loss of
sight in one eye and serious impairment of vision in the other
eye.3
* B.S. in Bus. Adm., West Virginia State College; Internal Revenue Officer,
Internal Revenue Service; Fourth-Year student at Cleveland-Marshall Law
School of Baldwin-Wallace College.
1 Neely v. St. Francis Hospital and School of Nursing Inc., 188 Kan. 546,
363 P. 2d 438 (1961).
2 Sanzari v. Rosenfield, 34 N. J. 128, 167 A. 2d 625 (1961). Defendant failed
to take a medical history from plaintiff before administering drug.
3 Johnston v. Brother, 190 Cal. App. 2d 464, 12 Cal. Rptr. 23 (1961).
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Do these cases suggest that one who suffers harm from the
administration of a new and dangerous drug has a cause of action
against the physician or hospital?
Further, does the advent of so many new drugs on the mar-
ket mean that new medico-legal standards of skill and care must
be used by the physician or hospital? 4
Before discussing these questions, we must look at three
problems: (1) What role does the physician play in the new drug
picture? (2) What are some of the new drugs and their side
effects, and (3) What steps must a new drug go through before
it is placed on the market for public consumption?
A physician is not liable if he prescribes a proper remedy or
treatment for a patient and it does not produce good results.5
The fact that the unfortunate results might have been prevented
will not render a physician liable unless he failed to use proper
skill and care.6
In the past it would appear that as long as a physician
thought a drug was proper, he would be safe in prescribing it.
Today's physician cannot safely rely on this rule of law in pre-
scribing drugs, and the reason is that it has been determined that
there are dangerous side effects in many of the new drugs.7
4 Oleck, New Medico-Legal Standards of Skill and Care, 11 Clev-Mar. L.
Rev. 443 (1962): "The lower the body of medical knowledge, generally the
lower is the legally required standard of a doctor's skill and care. Con-
versely, the higher the legal duty arises." For an example of the qualifica-
tion of a physician-expert on use of medication see, 1 Encyc. of Negligence
§ 218 (1962).
5 Morton v. U. S., 233 F. Supp. 1011 (No. Car. 1964); Ball v. Mallinkrodt
Chemical Works, 381 S. W. 2d 563 (Tenn. 1964). Where a contrast agent
selected was one used throughout the country a physician could not be
held liable when he used his best judgment in selecting the contrast agent:
Hill v. Boughton, 146 Fla. 505, 1 So. 2d 610 (1941), in which the court stated,
"If treatment recommended and applied by physician was proper treatment
for malady from which patient suffered, the physician would not be liable
for using such treatment though it did not produce good results."
6 Johnston v. Brother, supra n. 3. However if the physician fails to exercise
the care and skill required of him, it is no defense to a charge of negligence
that "he did the best he could." Schueler v. Strelinger, 204 A. 2d 577 (N. J.
1964).
7 Hunt, Side Effects: A New Worry For Doctors, Look Magazine (Dec. 31,
1963) p. 24. The article stated: "Not only are modem drugs a two-edged
sword; the same is true of nearly all modern diagnostic and therapeutic
procedures. This is no reason to avoid them, but it is reason for both doc-
tors and patients to weigh each use and make sure it is necessary and
important." For many illustrations of new drugs, cases, and effects see,
Oleck (ed.), Negligence & Compensation Service (bi-weekly, since 1955,
Central Book Co., Brooklyn, N. Y.) under the heading of "Drugs."
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As one writer observes: 8
Ninety percent of the prescription drugs now in use did not
exist 20 years ago. Virtually all antibiotics, steroids, anti-
histamines and tranquilizers have been developed and put
on the market since the average 45-year old doctor left med-
ical school. This flood of chemical creations threatens to nul-
lify the doctor's skills by outdating his training and adding
new data at a rate he cannot absorb while practicing his
profession...
The doctor's conscience and medical oath demand that he do
his best for his patients, rather than turn his back on the
host of new drugs. Yet to keep up with the output of pub-
lished reports on them is out of the question. (In 1962 the
National Library of Medicine estimated that about 200,000
articles on drugs are published each year.) In simple de-
spair, most doctors look for shortcuts; they learn about new
drugs first from the "detail men," the advance runners of
the drug companies, or from drug company advertising and
direct mail brochures.
8
No drug is absolutely safe for everyone. The problem is,
that if all the drugs bearing a risk were banned, there would be
hardly any drugs left. A medicine strong enough to influence a
disease is sure to have some effect on the body.
What are "detail men"? They are traveling salesmen
employed by the drug companies to make appointments with
doctors, and to sell the company's line of products.
It is estimated that as of 1960 there were 150,000 doctors in
the United States, and that the drug companies spent $750 mil-
lion on promotion of their products to these physicians, which
averages about $5,000 for every doctor in the country. It is fur-
ther estimated that the drug firms employ about 15,000 "detail
men" to push their products.9
To further complicate matters, the doctor is usually under
pressure from his patients for the latest cure. If he won't pre-
scribe it, they will go to another doctor who will.
Doctors are taught in medical school to write prescriptions
by the Latin name. However, thanks to the "detail men,"
it is estimated that 89 percent of doctors now prescribe drugs
by brand name rather than by the Latin name. One reason
8 Hunt, supra, n. 7; and see, "Drugs, How Safe is Safe Enough," Life (July 3,
1964) p. 37; "Drugs Worth Risk Taking," Science News Letter (March 21,
1964) p. 180.
9 Smith, The Health Hucksters (Cornwall Press, Cornwall, N. Y., 1960)
p. 88.
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for this could be that the companies have placed on the market
so many new drugs that most physicians do not feel competent in
making their own decisions about what to prescribe.' 0
In a recent case the Secretary of Health, Education and Wel-
fare, was made a defendant by 37 drug companies in an action
asking for a judgment declaring invalid new regulations pro-
mulgated by him. The regulation would have required that the
generic name be placed in conjunction with every appearance of
the trade name of the drug on labels and advertising. Verdict
was for plaintiffs."
Dr. Louis Lasagna of Johns Hopkins University states: 12
Investigators sometimes offered drugs on which extensive
safety tests have been run in animals, but sometimes, per-
haps by the same manufacturer, we are offered drugs on
which little animal work has been done. It is reprehensible
for man to be the first experimental animal on which tests
are run simply because by passing the tests in animals saves
time and money.
Dr. Charles D. May of New York University, a member of
the American Medical Association's Council on Drugs, testifying
before the Kefauver Committee on regulation of the drug in-
dustry, testified:
Hectic promotion of unwarranted products subjects patients
to illogical and excessive use of drugs. Individual doctors
cannot evaluate each drug's usefulness. If they could, they
would not have gone on prescribing leeches for so many
years.1
3
We therefore find that the physician plays one of the most
important roles in the prescribing of a new drug. This is so be-
cause he is the vehicle that is used to transport the drug from
the manufacturer to the consumer.
New Drugs and Their Side Effects
It is estimated that there have been 2 million allergic re-
actions since the advent of the drug "penicillin." 14 One of the
10 Ibid, p. 89.
11 Abbott Laboratories v. Celebrezze, 228 F. Supp. 855 (Del. 1964). The
original act required the established name to be prominently displayed on
drug labeling, but not every time the trade name was used.
12 "Doctors, Drugs, and Dollars," Time (August 4, 1961), p. 53; "Testing,"
Newsweek (Mar. 9, 1964) p. 52.
13 Ibid.
14 Current Medicine For Attorneys, 19 (Feb. 1963).
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most serious complications following the administration of peni-
cillin is the "immediate reaction." Within a few seconds to an
hour after administration of this drug the patient may experience
any of the following symptoms: generalized urticaria, asthma and
rhinitis, gastrointestinal or uterine cramps, unconsciousness, col-
lapse, and anaphylactic death. 15 Based on the projection of
statistics, it is reasonable to assume that from 100 to 300 such
fatal immediate type reactions occur annually in the United
States.16
It is not hard to balance these reliable figures against the
small discomforts of a cold, or against the known dangers of a
serious infection, to come to a rational decision whether to use
the drug. But all the data on the side effects of a new
drug are not nearly as reliable as this. After initial testing and
release by the Food and Drug Administration, side effect reports
of the drug appear slowly in the professional journals. 17
It is estimated that many of the approximately 1,230 doctors
who dispensed thalidomide to their patients without warning
them that they were to be human guinea pigs in the testing
of a new drug, have been raising their malpractice insurance
reportedly from $300,000 to $1,000,000.18 Thalidomide is a drug
taken by women in early pregnancy to relieve nausea, and by
others as a tranquilizer.
What medical testimony and government investigations had
failed to achieve through numerous reports, and hundreds of
hours, the thalidomide tragedy accomplished with sudden swift-
ness. The pill-taking public found that doctors and pharmaceuti-
cal companies are not infallible, and that the new pills flooding
the market at the rate of one every three days are not all miracle
drugs.1 9
Thalidomide in the United States was distributed as "Keva-
don" by the William S. Merrell & Company. A few years ago, a
15 Feinberg, "Allergy From Therapeutic Products," 178 J. A. M. A. 815
(Nov. 25, 1961).
16 For a case history of such a reaction see "Letters to the Editor,"
"Anaphylactoid Reaction To Demethylchlortetracycline Hydrochloride," 454
J. A. M. A. 181 (Aug. 4, 1962).
17 Hunt, op. cit. supra n. 7.
Is "Doctors in More Trouble," Parade Magazine (Oct. 7, 1962) p. 8.
19 "Tragedy From A Pill Bottle, Some Sad Lessons Learned," Newsweek
(Aug. 13, 1962) p. 52.
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2.5 million dollar damage suit was filed in the United States Dis-
trict Court against the William S. Merrell Company and Richard-
son-Merrell, the parent company of William S. Merrell Com-
pany. This suit was initiated by the parents of a child born with-
out arms as a result of the drug thalidomide. The suit alleged
that the drug was administered to the mother of the child in a
clinic during the second month of pregnancy. The petition al-
leged that the two firms were negligent in their failure to
properly determine whether the product was dangerous when
used by pregnant human females.2 0
Sometimes, after the most exhaustive tests, unexpected and
harmful side effects of a new drug are discovered only after the
drug has been put on the market.2 1 However, one new drug,
"Triparanol," sold by William S. Merrell Company under the
trade name of "Mer-29," clearly indicated in advance some of its
harmful effects. In applying for approval of this drug, Merrell
withheld information in its files that "Triparanol" had caused
cataracts in animals. In March 1964, the Merrell Company went
on trial with three of its executives, and its parent company,
Richardson-Merrell, Inc., on twelve counts of supplying the Food
and Drug Administration with false, fictitious and fraudulent
data. The company and its executives pleaded nolo contendere
on eight counts. 22
In a recent civil action arising from use of the same drug,
Mer-29, the William S. Merrell Company was named defendant
in a suit filed in the United States District Court in Illinois.
The complaint charges the Merrell Company with knowingly
and negligently causing the plaintiffs to suffer eye cataracts, and
numerous other nerve, muscle and tissue damage by marketing
Mer-29.23 The drug, withdrawn from the market in April 1962,
was intended to reduce high blood cholesterol counts.2 4
Another popular new drug is a pill that is being taken by
females as an oral contraceptive to prevent pregnancy. It is
principally known by the trade name of "Enovid." It has been
stated, however, that these popular drugs are still in the experi-
20 Current Medicine For Attorneys, p. 19 (Feb. 1963).
21 "Triparanol Side Effects," Time (April 3, 1964) p. 79.
22 Ibid.
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mental stage and that not enough scientific data has been gath-
ered to know if they are really safe or not.25
A report by the American College of Surgeons indicated
that these drugs may work on the body in a manner that extends
the fertile period until the time of menopause, resulting in
pregnant grandmothers. It is believed that the young women
who are consulting doctors for oral contraceptives do not expect
to become pregnant grandmothers. The doctor therefore, under
the doctrine of informed consent, has a duty to inform all of his
young female patients to whom he prescribes this drug, that it is
possible that her child-bearing years may be extended, and when
the woman is fifty, and has supposedly ended her period of con-
ception, she may possibly become pregnant. 26 This then would
be a new medico-legal standard of care on the part of a physi-
cian, from which a malpractice action might spring if it is neg-
lected. Another possible side effect that may stem from the use
of this drug is unexpected bleeding. The drug also alters physio-
logical processes.27
Another antibiotic that gives a reaction similar to penicillin
is "Neomycin." 28
The use of serums and vaccines may cause allergic reac-
tions called "serum sickness," which produces symptoms similar
to the ones seen in penicillin reactions. The doctor has a duty to
pre-test any patients who are to receive any horse serum ex-
tracts. Not all horse dander sensitive patients are allergic to the
serums, but when they are, they are usually more allergic than
those who acquired their sensitivity by a prior serum inocula-
tion. Tetanus toxoid should be used in allergic individuals and
is considered a must for persons who are horse serum sensitive.
29
Tetanus antitoxin may produce a very serious serum sickness.30
25 DeCosta, "Those Deceptive Contraceptives," 181 J. A. M. A. 122 (July 14,
1962).
26 Ringrose, "Pregnant Grandmas? Blame Oral Contraceptives," 182 A. M.
A. J. 28 (Oct. 27, 1962).
27 DeCosta, op. cit. supra, n. 25.
28 Marchese v. Monaco, 52 N. J. 474, 145 A. 2d 809 (1958). The plaintiff was
treated with "mycifradin" which is the trade name for "neomycin," and as
a result of negligent treatment became deaf. Plaintiff was awarded dam-
ages in the amount of $56,000.
29 Feinberg, op. cit. supra n. 15.
30 Gorlin v. Master, 180 N. Y. S. 2d 84 (1958). A scratch test was given to
plaintiff prior to injection of tetanus antitoxin. Such injection resulted in
(Continued on next page)
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Iodine preparations used in X-Ray diagnosis can produce
severe reactions.8 '
On September 17, 1964, the United States Food and Drug
Administration released a publication which stated that:
Dr. Joseph F. Sadush, Jr., Medical Director of F. D. A., said
that since 1959, 40 reports of blood dyscrasias associated with
dipyrone ingestion, with 13 fatalities, have been collected by
the American Medical Association. la
The drugs aminophrine and dipyrone are pain killing drugs, and
are considered responsible for at least 26 deaths occurring large-
ly in Europe. 32
The new drugs that are responsible for causing diseases
are far too many to list here. The few mentioned will give an
idea of how dangerous some of the new drugs may be. It is
obvious that from the dangerous propensities of these drugs, the
physician has a high standard of care in prescribing them for
his patient.
Steps Before Releasing New Drugs
What is a "new drug"? Under the 1962 amendments to the
Federal Food, Drug and Cosmetic Act, it is defined as a drug
not recognized by experts as safe and effective. A further classi-
fication of this definition would be:
If labeling of the drug represents it for prevention or treat-
ment of a condition for which qualified experts do not recog-
nize it as effective, then the drug is a "new drug." 33
Dr. Frances 0. Kelsey, Chief of the Investigational Drug
Branch of the Division of New Drugs, F. D. A., in a seminar
conducted at La Jolla, California, on April 5 and 10, 1963 stated
that a new drug is not necessarily an entirely new entity, but
may be an old drug prepared for a new use, a combination of
(Continued from preceding page)
the plaintiff contracting serum poisoning. However the court commented:
"Indeed failure to administer it, regardless of the possibility of allergic re-
action, might be medically unsound and reprehensive."
31 Horace v. Weyrauch, 159 Cal. App. 2d 833, 324 P. 2d 666, 64 A. L. R. 2d
1276 (1958).
hia U. S. Department of Health, Education, and Welfare, Food and Drug
Administration, Release No. HEW C53 (Aug. 17, 1964).
3Z "Debate Drug Use," The Cleveland Press, Home Edition (Sept. 7, 1964)
p. F-7.
33 U. S. Department of Health, Education and Welfare; Food and Drug Ad-
ministration, Publication Number 5, 1963, p. 1.
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two or more old drugs, or it may be a new drug because it con-
tains a new component such as an excipient, carrier, coating or
menstruum.
Dr. Kelsey is the F. D. A. doctor who prevented thalidomide
from becoming the tragedy in America that it was in Europe, by
refusing to approve the new drug application submitted by the
manufacturer. In fact, it was the drug "thalidomide" that caused
Congress to pass the 1962 amendment to the Federal Food, Drug
and Cosmetic Act. 34
To get a safety clearance, the manufacturer must submit a
new drug application to the F. D. A. In the application, any
information about the drug that would affect its safety, such as
results of tests on human beings, results of tests on animals, the
ingredients, and the amounts of each in the formula, description
of manufacturing procedures, all labels and accompanying liter-
ature; and qualifications of personnel must be stated.35
The results of human and animal testing, and the other
information in the application, are then studied carefully by
F. D. A. doctors and chemists, who are specialists in drug testing.
These experts must be satisfied that the drug can be used safely,
and that the proposed label contains all important information
and warnings about possible side effects, and any other infor-
mation necessary for safe use.3 6
If the drug can be safely used only by a physician or under
his care, it will be released for sale by prescription only.
3 7
Most new drugs are released for prescription sale only, at
first, because this provides an extra safety factor while more
experience with the drug is being obtained. However, if it is
demonstrated that the new drug can be used safely without
34 "Towards Safer Drugs," Consumer Reports (Oct. 1962), p. 509: "That
thalidomide was not cleared for sales here was more luck than anything
else. If it had been developed here instead of in Germany, it probably
would have been cleared. Pre-marketing safety tests considered adequate
before the thalidomide incident probably would not have revealed the
drug's dangers."
35 U. S. Department of Health, Education, and Welfare; Food and Drug
Administration, op. cit. supra n. 33, p. 2. Smith, "New Drug Application,"
17 Food Drug & Cosmetics L. J. 497 (1962).
36 Ibid, pp. 2, 4. Sec. 102(b) 76 Stat. 781 (1962). The manufacturer must
show by substantial evidence that the drug has the effect claimed or sug-
gested on its labeling. This section of the statute also lists the grounds for
refusal of a new drug application.
37 Ibid., p. 2.
Sept., 1965
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medical supervision, it may be released for sale without pre-
scription. The labeling of the package for consumer use must
then contain adequate instructions and warning for the ultimate
user.
s8
Experimental drugs are exempted from the aforementioned
requirement of the Act when shipped to qualified investigators
for research.3 9 There are many other requirements that must be
met by the manufacturer before the drug is released by F. D. A.,
but the steps mentioned are the basic ones.soa
Although no case in point can be cited, it is believed that
most courts would still hold the physician liable for negligently
administering a new drug, even though it was approved by the
F. D. A. prior to dispensing by the doctor.
Standards of Care
A question of the duty owed always arises in cases of medical
malpractice.40
A physician in treating a patient impliedly represents that
he possesses, and the law gives him the duty of possessing, that
reasonable degree of skill and learning that is ordinarily pos-
sessed by physicians in the community in which he practices who
are engaged in the same line of practice.41
An analysis of this rule reveals a further duty, that the phy-
sician must stay abreast of the times, and must follow the ap-
proved methods in general use.42 Courts have held that it is the
38 Ibid.
39 Ibid., p. 6.
39a "Drugs Makers v. Review," Science News Letter (Aug. 8, 1964) p. 94.
"Drugs, Safety, and Effectiveness," Time (Mar. 13, 1964) p. 82.
40 Parkell v. Fitzporter, 301 Mo. 217, 256 S. W. 239 (1923); Edwards v.
Lamb, 69 N. H. 599, 45 A. 480 (1899); Prosser, Law of Torts 231 (3rd ed.
1964).
41 Richardson v. Doe, 176 Ohio St. 370, 199 N. E. 2d 878 (1964); Wells v.
McGehee, 39 So. 2d 196 (La. App. 1949); Wolfsmith v. Marsh, 51 Cal. 2d 832,
337 P. 2d 70 (1959). In DeLaughter v. Womack, 164 So. 2d 762 (Miss. 1964),
the defendant physician contended that the proximate cause of plaintiff's
injury was an allergic reaction to an injection of penicillin for which he
had pre-tested. Plaintiff contended that the injection was negligently ad-
ministered. See also, Norton v. Argonaut Ins. Co., 144 So. 2d 249 (La. App.
1962); Snyder v. Pantaleo, 143 Conn. 290, 122 A. 2d 21 (1956); Ardoline v.
Keegan, 140 Conn. 552, 102 A. 2d 352 (1954).
42 Bowers v. Santee, 99 Ohio St. 361, 367, 124 N. E. 238 (1919). Oleck, op. cit.
supra n. 4, at p. 447. states: "Establishment of new services and infor-
(Continued on next page)
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duty of a physician to avail himself of more advanced and fav-
orable modes of treatment facilities and training than might be
present in the community in which he practices, because easier
means of communication and transportation now exist.43
However, a pure accident, or a mistaken diagnosis which
happens in spite of all reasonable precautions, usually are not
enough to show lack of care and skill.44
In "harmful drug" actions, as in other malpractice suits, this
lack of care and skill must rest upon the testimony of an expert
witness who is qualified to express an opinion as to the standard
of care usually exercised by physicians in the same community
where the treatment complained of was administered. 45
In a recent case the plaintiff sued his physician for negli-
gently causing an allergic reaction by placing the drug "neo-
synephrine" in his eyes without testing to determine if he was
allergic to it.46 In holding for the defendant, the court stated
that a patient has no cause of action against his physician either
in treatment or diagnosis, unless he proves by an expert witness
of the same school of medicine as the defendant that the injury
complained of was negligently administered, and that it was the
proximate cause of the plaintiff's injuries.
In a case decided in 1964 by a California court the plaintiff
recovered substantial damages against a physician who adminis-
(Continued from preceding page)
mation sources for physicians are likely to affect the physician's standard of
skill and care. For example, a new telephone and/or mail information serv-
ice makes available to physicians complete data on any drug, on a routine
or emergency basis. This service, centered in Washington, D. C., cost $15/
year, and had a file of 15,000 separate drug descriptions by late 1961. Avail-
ability of this service may make less easily excusable a physician's lack of
data on available drugs."
43 Tvedt v. Haugen, 70 N. D. 338, 294 N. W. 183 (1940); Cook v. Lichtblau,
144 So. 2d 312 (Fla. App. 1962).
44 Meador v. Arnold, 264 Ky. 378, 94 S. W. 2d 626 (1936); Gorlin v. Master,
supra n. 30; Wilson v. St. Francis Hospital and School of Nursing, Inc., 190
Kan. 150, 373 P. 2d 180 (1962). Plaintiff suffered an anaphylastic reaction as
the result of an injection of tetanus antitoxin, and where there was a posi-
tive reaction to a sensitivity test administered prior to the injection. The
court observed that where there was a possibility of tetanus infection, it
would be negligence on the part of the physician not to give a tetanus anti-
toxin injection even in the face of a positive reaction.
45 Ardoline v. Keegan, supra n. 41; Stryker, Courts and Doctors 84 (Mac-
Millan Co., New York, 1932); Johnston v. Brother, supra n. 3; Sinz v. Owens,
33 Cal. 749, 205 P. 2d 3 (1949). For an excellent discussion on expert wit-
nesses see: Trial Tactics in Handling The Medical Expert Witness, 29 Tenn.
L. Rev. 208 (1962).
46 Scott v. Leigh, 355 S. W. 2d 798 (Tex. Civ. App., 1962).
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tered the antibiotic "chloromycetin" which is the trade name for
chloramphenicol, a wide spectrum antibiotic.4 7 The plaintiff was
treated on two occasions by the physician, who both times recom-
mended the drug "chloromycetin." Altogether 96 capsules of
250 milligrams each were dispensed to the plaintiff. The phy-
sician took no culture or blood test during the period of treat-
ment. Nine months later, the plaintiff was diagnosed as having
aplastic anemia. Aplastic anemia is a rare and very often fatal
disease (approximately 1,000 fatal cases occur annually in the
U. S.). The expert witness for the plaintiff testified that the
drug was a valuable antibiotic if used properly, but stated that
its use was dangerous, attended by serious risk, and that it
should only be prescribed for a very limited number of diseases.
It is only in a case where there is manifest such obvious
gross lack of care or skill as to afford, of itself, an almost con-
clusive inference of want of care, that the testimony of an expert
witness is not necessary. 4 This type of situation is often referred
to as one of "res ipsa loquitur."
In Morgensen v. Hicks,49 the plaintiff sued his physician, the
pharmaceutical company that produced the anesthesia, the hos-
pital where the services were rendered, and the druggist who
sold the drug, as a result of an allergic reaction suffered from
the administration of the drug "pyribenzamine." The court re-
fused to apply the doctrine of res ipsa loquitur, and gave two
reasons: (1) That the instrumentalities causing the injury were
not in the full control of the doctor, and (2) the allergic reaction
of the plaintiff was beyond the doctor's control. In rejecting the
doctrine, the court said:
The doctor's contacts are with the frailties, idiosyncrasies,
physical and mental weaknesses and allergies of human na-
ture. They may affect the condition, and yet are beyond his
control.
47 Love v. Wolf, 38 Cal. Rptr. 183 (Cal. App. 1964).
48 Grantham v. Goetz, 401 Pa. 349, 164 A. 2d 225 (1960). The plaintiff was
given an intravenous injection of a drug known as "Levophed." This drug
is a blood vessel constrictor utilized to increase the blood pressure in case
of shock. The drug caused a blister to form, and skin tissue was burned.
In ruling for the defendant the court commented: "No presumption or in-
ference of negligence arises merely because the medical care or surgical
operation terminated in an unfortunate result which might have occurred
even though proper care and skill had been exercised." See also, Prosser,
op. cit. supra n. 40, at 231, 232. Toy v. Rickert, 53 N. J. 27, 146 A. 2d 510
(1958) involved injury from penicillin; the court, after much discussion,
rejected the contentions for applying the doctrine of res ipsa loquitur.
49 253 Iowa 139, 110 N. W. 2d 563 (1961).
12https://engagedscholarship.csuohio.edu/clevstlrev/vol14/iss3/8
14 CLEV-MAR. L. R. (3)
In Sanzari v. Rosenfield,50 the court decided that the doc-
trine of "res ipsa" should at least allow a jury to infer negligence
so as to avoid a dismissal at the end of the plaintiff's case. The
court in this case invoked the "common knowledge doctrine,"
which permits the jury to apply the standard of care that should
have been used.
The physician or hospital has the duty to give a skin sensi-
tivity test before administering drugs such as penicillin, tetanus
antitoxin, and other antibiotics in order to determine the pa-
tient's allergic reactions.5 ' Failure to do so may render the
physician liable for lack of due care.52
There is usually a prescribed waiting time between giving
the sensitivity test and administering the drug. 53 Failure to wait
the prescribed time may render one liable for damages. 54
Recently, the legal doctrine of "informed consent" has arisen
in the United States. In the few cases tried under this doctrine,
the courts have held that a physician must explain to the patient
the risks involved in the treatment.55
A physician who treats a patient and furnishes pills to be
taken internally which he represents as harmless and safe,
whereas such pills contain "dinitrophenol," a harmful, danger-
ous, and unofficial drug, by such representation warrants their
50 Supra n. 2.
51 Snyder v. Pantaleo, supra n. 41; defendant physician after learning that
plaintiff had no "known" allergies, gave her a skin test, which showed a
one plus reaction. Disregarding the test, he administered 20 cc. of drug
"diodrast," which caused plaintiff to suffer convulsions. The court held for
plaintiff.
52 Yorston v. Pennell, 397 Pa. 28, 153 A. 2d 255 (1959). Patient was given
skin test for tetanus antitoxin, but not penicillin. The court noted that:
"Medical testimony shows that of all the antibiotics penicillin is the one
most likely to cause allergic reactions, and this has been known since 1943.
Such reactions may occur immediately, that is, within a minute or two or
as much as four weeks later, and can have serious consequences involving
the brain, nerves, gastrointestinal tract, skin and the blood."
53 Neely v. St. Francis Hospital and School of Nursing, Inc., supra n. 1.
The expert witness for the plaintiff testified, "Throughout the country the
universal practice was to wait not less than 10 minutes and if the shot
was in the upper arm one should wait at least 30 minutes." Witness testified
that not more than 5 minutes elapsed between the test and the injection.
54 Ibid.
55 Woods v. Brumlop, 71 N. M. 221, 377 P. 2d 520 (1962). Hirsch, "Informed
Consent to Treatment," 176 J. A. M. A. 436 (1961). Natanson v. Kline, 186
Kan. 393, 350 P. 2d 1093 (1960); DiFlippo v. Preston, 53 Del. 539, 173 A. 2d
333 (1961).
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safety, and is liable for breach of warranty, regardless of any
negligence in administering them. This warranty also may ex-
tend to the drug manufacturer. 6
A physician in California was suspended from practicing
medicine for 180 days for violation of a statute making it unpro-
fessional conduct to prescribe dangerous drugs without either
prior examination or medical indication thereof. The physician
prescribed the drug "Seconal," a dangerous drug, without exam-
ining the patient.57
Conclusion
We must conclude from these facts that physicians are not
justified in prescribing potentially dangerous drugs for trivial
ills, that physicians and hospitals have the duty to test or at least
inquire about any allergies that the patient may possess, and that
the medical profession and public alike must learn that all new
drugs are not magical cures for all the ailments that beset us.
56 Morningstar v. Jones, 31 Ohio L. Abs. 440 (1940). A case brought under
the Ohio Uniform Commercial Code (adopted July 1, 1963) may bring a
different result. Gottsdanker v. Cutter Laboratories, 182 Cal. App. 2d 602,
6 Cal. Rptr. 320 (1960): Defendant found guilty for breach of implied
warranty of merchantability in that a drug which was intended for intro-
duction into the body of a human being contained a live poliomyelitis germ.
Rheingold, Products Liability-The Ethical Drug Manufacturer's Liability,
18 Rutgers L. R. 947 (1964) is an excellent article that discusses the stand-
ards of care a drug manufacturer must use in giving adequate warnings to
the public in the sale of new drugs.
57 Sunseri v. Board of Medical Examiners, 36 Cal. Rptr. 553 (Cal. App.,
1964).
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